-
The American Journal of Cardiology Apr 2021Patients with homozygous familial hypercholesterolemia (HoFH) have a high risk for premature death. Supravalvular aortic stenosis (SVAS) is a common and the feature...
Patients with homozygous familial hypercholesterolemia (HoFH) have a high risk for premature death. Supravalvular aortic stenosis (SVAS) is a common and the feature lesion of the aortic root in HoFH. The relation between SVAS and the risk of premature death in patients with HoFH has not been fully investigated. The present study analysis included 97 HoFH patients with mean age of 14.7 (years) from the Genetic and Imaging of Familial Hypercholesterolemia in Han Nationality Study. During the median (±SD) follow-up 4.0 (±4.0) years, 40 (41.2%) participants had SVAS and 17 (17.5%) participants experienced death. The proportion of premature death in the non-SVAS and SVAS group was 7.0% and 32.5%, respectively. Compared with the non-SVAS group, SVAS group cumulative survival was lower in the HoFH (log-rank test, p <0.001). This result was further confirmed in the multivariable Cox regression models. After adjusting for age, sex, low density lipoprotein cholesterol (LDL_C)-year-score, lipid-lowering drugs, cardiovascular disease, and carotid artery plaque, SVAS was an independent risk factor of premature death in HoFH on the multivariate analysis (hazard ratio 4.45; 95% confidence interval, 1.10 to 18.12; p = 0.037). In conclusion, a significantly increased risk of premature death was observed in HoFH patients with SVAS. Our study emphasized the importance of careful and aggressive management in these patients when appropriate.
Topics: Adolescent; Adult; Aortic Stenosis, Supravalvular; Apolipoprotein B-100; Arcus Senilis; Carotid Stenosis; Case-Control Studies; Cause of Death; Child; Child, Preschool; Echocardiography; Female; Follow-Up Studies; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Infant; Male; Mortality, Premature; Multivariate Analysis; Proportional Hazards Models; Proprotein Convertase 9; Receptors, LDL; Risk; Risk Factors; Xanthomatosis; Young Adult
PubMed: 33454344
DOI: 10.1016/j.amjcard.2020.12.080 -
Journal of Biomedical Physics &... Aug 2020Arcus Senilis (AS) appears as a white, grey or blue ring or arc in front of the periphery of the iris, and is a symptom of abnormally high cholesterol in patients under...
BACKGROUND
Arcus Senilis (AS) appears as a white, grey or blue ring or arc in front of the periphery of the iris, and is a symptom of abnormally high cholesterol in patients under 50 years old.
OBJECTIVE
This work proposes a deep learning approach to automatic recognition of AS in eye images.
MATERIAL AND METHODS
In this analytical study, a dataset of 191 eye images (130 normal, 61 with AS) was employed where ¾ of the data were used for training the proposed model and ¼ of the data were used for test, using a 4-fold cross-validation. Due to the limited amount of training data, transfer learning was conducted with AlexNet as the pretrained network.
RESULTS
The proposed model achieved an accuracy of 100% in classifying the eye images into normal and AS categories.
CONCLUSION
The excellent performance of the proposed model despite limited training set, demonstrate the efficacy of deep transfer learning in AS recognition in eye images. The proposed approach is preferred to previous methods for AS recognition, as it eliminates cumbersome segmentation and feature engineering processes.
PubMed: 32802798
DOI: 10.31661/jbpe.v0i0.2003-1080 -
QJM : Monthly Journal of the... Aug 2021
Topics: Arcus Senilis; Cornea; Dyslipidemias; Humans
PubMed: 32770245
DOI: 10.1093/qjmed/hcaa236 -
Indian Journal of Ophthalmology Oct 2019
Topics: Aged; Arcus Senilis; Cataract; Cataract Extraction; Cornea; Humans; Male; Visual Acuity
PubMed: 31546532
DOI: 10.4103/ijo.IJO_402_19 -
Australian Journal of General Practice Sep 2019
Topics: Anticholesteremic Agents; Arcus Senilis; Cholesterol; Cholesterol, LDL; Coronary Disease; Diet; General Practice; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Life Style; Medical History Taking; Phenotype; Risk Reduction Behavior; Xanthomatosis
PubMed: 31476827
DOI: 10.31128/AJGP-04-19-4910